Literature DB >> 22915796

Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses.

Yunjeong Kim1, Scott Lovell, Kok-Chuan Tiew, Sivakoteswara Rao Mandadapu, Kevin R Alliston, Kevin P Battaile, William C Groutas, Kyeong-Ok Chang.   

Abstract

Phylogenetic analysis has demonstrated that some positive-sense RNA viruses can be classified into the picornavirus-like supercluster, which includes picornaviruses, caliciviruses, and coronaviruses. These viruses possess 3C or 3C-like proteases (3Cpro or 3CLpro, respectively), which contain a typical chymotrypsin-like fold and a catalytic triad (or dyad) with a Cys residue as a nucleophile. The conserved key sites of 3Cpro or 3CLpro may serve as attractive targets for the design of broad-spectrum antivirals for multiple viruses in the supercluster. We previously reported the structure-based design and synthesis of potent protease inhibitors of Norwalk virus (NV), a member of the Caliciviridae family. We report herein the broad-spectrum antiviral activities of three compounds possessing a common dipeptidyl residue with different warheads, i.e., an aldehyde (GC373), a bisulfite adduct (GC376), and an α-ketoamide (GC375), against viruses that belong to the supercluster. All compounds were highly effective against the majority of tested viruses, with half-maximal inhibitory concentrations in the high nanomolar or low micromolar range in enzyme- and/or cell-based assays and with high therapeutic indices. We also report the high-resolution X-ray cocrystal structures of NV 3CLpro-, poliovirus 3Cpro-, and transmissible gastroenteritis virus 3CLpro- GC376 inhibitor complexes, which show the compound covalently bound to a nucleophilic Cys residue in the catalytic site of the corresponding protease. We conclude that these compounds have the potential to be developed as antiviral therapeutics aimed at a single virus or multiple viruses in the picornavirus-like supercluster by targeting 3Cpro or 3CLpro.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22915796      PMCID: PMC3486288          DOI: 10.1128/JVI.01348-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

Review 1.  Telaprevir user's guide.

Authors:  AnnMarie Liapakis; Ira Jacobson
Journal:  Clin Liver Dis       Date:  2011-08       Impact factor: 6.126

2.  New human renin inhibitors containing an unnatural amino acid, norstatine.

Authors:  K Iizuka; T Kamijo; T Kubota; K Akahane; H Umeyama; Y Kiso
Journal:  J Med Chem       Date:  1988-04       Impact factor: 7.446

3.  Design, synthesis, and evaluation of inhibitors of Norwalk virus 3C protease.

Authors:  Kok-Chuan Tiew; Guijia He; Sridhar Aravapalli; Sivakoteswara Rao Mandadapu; Mallikarjuna Reddy Gunnam; Kevin R Alliston; Gerald H Lushington; Yunjeong Kim; Kyeong-Ok Chang; William C Groutas
Journal:  Bioorg Med Chem Lett       Date:  2011-07-14       Impact factor: 2.823

4.  On the size of the active site in proteases. I. Papain.

Authors:  I Schechter; A Berger
Journal:  Biochem Biophys Res Commun       Date:  1967-04-20       Impact factor: 3.575

5.  alpha-Hydroxy phosphinyl-based inhibitors of human renin.

Authors:  D V Patel; K Rielly-Gauvin; D E Ryono; C A Free; W L Rogers; S A Smith; J M DeForrest; R S Oehl; E W Petrillo
Journal:  J Med Chem       Date:  1995-10-27       Impact factor: 7.446

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  Design of wide-spectrum inhibitors targeting coronavirus main proteases.

Authors:  Haitao Yang; Weiqing Xie; Xiaoyu Xue; Kailin Yang; Jing Ma; Wenxue Liang; Qi Zhao; Zhe Zhou; Duanqing Pei; John Ziebuhr; Rolf Hilgenfeld; Kwok Yung Yuen; Luet Wong; Guangxia Gao; Saijuan Chen; Zhu Chen; Dawei Ma; Mark Bartlam; Zihe Rao
Journal:  PLoS Biol       Date:  2005-09-06       Impact factor: 8.029

8.  An episulfide cation (thiiranium ring) trapped in the active site of HAV 3C proteinase inactivated by peptide-based ketone inhibitors.

Authors:  Jiang Yin; Maia M Cherney; Ernst M Bergmann; Jianmin Zhang; Carly Huitema; Hanna Pettersson; Lindsay D Eltis; John C Vederas; Michael N G James
Journal:  J Mol Biol       Date:  2006-07-07       Impact factor: 5.469

Review 9.  Coronaviruses post-SARS: update on replication and pathogenesis.

Authors:  Stanley Perlman; Jason Netland
Journal:  Nat Rev Microbiol       Date:  2009-06       Impact factor: 60.633

10.  Individual and common inhibitors of coronavirus and picornavirus main proteases.

Authors:  Chih-Jung Kuo; Hun-Ge Liu; Yueh-Kuei Lo; Churl-Min Seong; Kee-In Lee; Young-Sik Jung; Po-Huang Liang
Journal:  FEBS Lett       Date:  2009-01-21       Impact factor: 4.124

View more
  133 in total

1.  Enterovirus D68 Antivirals: Past, Present, and Future.

Authors:  Yanmei Hu; Rami Musharrafieh; Madeleine Zheng; Jun Wang
Journal:  ACS Infect Dis       Date:  2020-05-14       Impact factor: 5.084

2.  Putative structural rearrangements associated with the interaction of macrocyclic inhibitors with norovirus 3CL protease.

Authors:  Anushka C Galasiti Kankanamalage; Pathum M Weerawarna; Athri D Rathnayake; Yunjeong Kim; Nurjahan Mehzabeen; Kevin P Battaile; Scott Lovell; Kyeong-Ok Chang; William C Groutas
Journal:  Proteins       Date:  2019-04-01

3.  Structural and dynamics characterization of norovirus protease.

Authors:  Daisuke Takahashi; Yasuaki Hiromasa; Yunjeong Kim; Asokan Anbanandam; Xiaolan Yao; Kyeong-Ok Chang; Om Prakash
Journal:  Protein Sci       Date:  2013-01-27       Impact factor: 6.725

4.  Nonnucleoside inhibitors of norovirus RNA polymerase: scaffolds for rational drug design.

Authors:  Auda A Eltahla; Kun Lee Lim; John-Sebastian Eden; Andrew G Kelly; Jason M Mackenzie; Peter A White
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

5.  The p4-p2' amino acids surrounding human norovirus polyprotein cleavage sites define the core sequence regulating self-processing order.

Authors:  Jared May; Prasanth Viswanathan; Kenneth K-S Ng; Alexei Medvedev; Brent Korba
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

Review 6.  Current tools for norovirus drug discovery.

Authors:  Sahani Weerasekara; Allan M Prior; Duy H Hua
Journal:  Expert Opin Drug Discov       Date:  2016-05-02       Impact factor: 6.098

7.  Structural and inhibitor studies of norovirus 3C-like proteases.

Authors:  Daisuke Takahashi; Yunjeong Kim; Scott Lovell; Om Prakash; William C Groutas; Kyeong-Ok Chang
Journal:  Virus Res       Date:  2013-09-17       Impact factor: 3.303

Review 8.  Treatment of norovirus infections: moving antivirals from the bench to the bedside.

Authors:  Stuart S Kaufman; Kim Y Green; Brent E Korba
Journal:  Antiviral Res       Date:  2014-02-25       Impact factor: 5.970

9.  Structure-guided design and optimization of dipeptidyl inhibitors of norovirus 3CL protease. Structure-activity relationships and biochemical, X-ray crystallographic, cell-based, and in vivo studies.

Authors:  Anushka C Galasiti Kankanamalage; Yunjeong Kim; Pathum M Weerawarna; Roxanne Adeline Z Uy; Vishnu C Damalanka; Sivakoteswara Rao Mandadapu; Kevin R Alliston; Nurjahan Mehzabeen; Kevin P Battaile; Scott Lovell; Kyeong-Ok Chang; William C Groutas
Journal:  J Med Chem       Date:  2015-03-19       Impact factor: 7.446

Review 10.  Recent Advances in the Discovery of Norovirus Therapeutics.

Authors:  Yunjeong Kim; Anushka C Galasiti Kankanamalage; Kyeong-Ok Chang; William C Groutas
Journal:  J Med Chem       Date:  2015-08-17       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.